Severe Hypertriglyceridemia in Human APOC1 Transgenic Mice is Caused by ApoC1-Induced Inhibition of LPL

Jimmy F.P. Berbée1,2, Caroline C. van der Hoogt1,2, Deepa Sundararaman1,2, Louis M. Havekes1,2,3, Patrick C.N. Rensen1,2

1TNO-Prevention and Health, Gaubius Laboratory, P.O. Box 2215, 2301 CE Leiden, The Netherlands; Departments of 2General Internal Medicine and 3Cardiology, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands

Published in J Lipid Res. 2005; 46(2): 297-306
Objective - Studies in humans and mice have shown that increased expression of apo-CI results in combined hyperlipidemia with a more pronounced effect on triglycerides (TG) as compared to total cholesterol (TC). The aim of this study was to elucidate the main reason for this effect using human apoCI-expressing (APOC1) mice.

Methods and Results - Moderate plasma human apoCI levels (i.e. 4-fold higher than human levels), caused a 12-fold increase in TG, along with a 2-fold increase in TC, mainly confined to VLDL. Cross-breeding of APOC1 mice on an apoE-deficient background resulted in a marked 55-fold increase in TG, confirming that the apoCI-induced hyperlipidemia cannot merely be attributed to blockade of apoE-recognizing hepatic lipoprotein receptors. The plasma half-life of [3H]TG-VLDL-mimicking particles was 2-fold increased in APOC1 mice, suggesting that apoCI reduces the lipolytic conversion of VLDL. While total post-heparin plasma LPL activity was not lower in APOC1 mice as compared to controls, apoCI was able to dose-dependently inhibit the LPL-mediated lipolysis of [3H]TG-VLDL-mimicking particles in vitro, with a 60% efficiency as compared to the main endogenous LPL inhibitor apoCIII. Finally, purified apoCI impaired the clearance of [3H]TG-VLDL-mimicking particles independent of apoE-mediated hepatic uptake, in lactoferrin-treated mice.

Conclusion - Therefore, we conclude that apoCI is a potent inhibitor of LPL-mediated TG lipolysis.
The human apolipoprotein CI (apoCI)-encoding gene APOC1 is part of the APOE/APOC1/APOC2 gene cluster. ApoCI is primarily expressed in the liver, but also in the lung, skin, spleen, adipose tissue, and brain. ApoCI is secreted as a 6.6-kD protein into the plasma, where it is present at a relatively high concentration of approximately 10 mg/dl, and is mainly bound to chylomicrons, VLDL and HDL. Although human studies have not revealed any polymorphism in the APOC1 gene leading to functional apoCI variants thus far, an HpaI polymorphism in the promotor region has been described that leads to 57% increased expression of the APOC1 gene. Interestingly, HpaI carriers display increased plasma triglyceride (TG) levels, which are independent of total cholesterol (TC) levels. To get more insight into the function of apoCI in lipoprotein metabolism, we and others have generated mice that either lack endogenous apoCI or express the human APOC1 gene. Although apoCI-deficient mice did not show a phenotype with respect to plasma lipid levels, APOC1 transgenic mice indeed showed an APOC1 gene dose-dependent increase in plasma levels of TG, TC, and free fatty acids (FFA). The most prominent increasing effect of APOC1 was observed on TG levels, and could be attributed to severely increased levels of VLDL.

Early reports have postulated that apoCI may function by both modulation of the activity of plasma enzymes involved in lipid metabolism and by modulation of TG-rich lipoprotein (remnant) binding and uptake by hepatic receptors. In vitro studies have shown that apoCI may interfere with VLDL metabolism by partial activation of lecithin:cholesterol acyl transferase (LCAT), inhibition of lipoprotein lipase (LPL) and inhibition of hepatic lipase (HL). Recently, Conde-Knapke et al. have confirmed such an HL-modulating function of apoCI in vitro, and have suggested that HL modulation may contribute to the hypertriglyceridemic phenotype of APOC1 transgenic mice. Strikingly, HL-deficient mice do not show any sign of disturbed TG metabolism. In addition, LCAT transgenic mice do not show elevated VLDL, suggesting that potential LCAT-activating properties of apoCI do not contribute to the phenotype of APOC1 mice.

Besides modulation of plasma enzymes, apoCI has also been reported to interfere with the apoE-dependent hepatic uptake of lipoprotein remnants by the LDL receptor (LDLr) and LDLr-related protein (LRP). In the isolated rat liver perfusion model, it was demonstrated that addition of human apoCI inhibits the catabolism of chylomicrons and TG-rich emulsions. Subsequently, it was shown that apoCI can interfere with the apoE-mediated uptake of VLDL by the LDLr and LRP, possibly related to apoCI-induced masking of the receptor binding domain of apoE or displacement of apoE from the lipoprotein particle. More recent studies from our group have suggested that the inhibiting properties of apoCI towards the LRP may exceed those towards the LDLr, since the apoCI-associated hyperlipidemia was severely aggravated on an LDLr-deficient background. In addition, it was shown that transfection of ldlr-/-APOC1 mice with a recombinant adenovirus encoding the 39-kDa receptor associated protein (RAP) further increased plasma TG levels 4-fold. However, although these studies certainly point at a modulating role of apoCI with respect to hepatic lipoprotein recognition, it remains remarkable that complete blockade of the apoE-mediated lipoprotein clearance in apoE-deficient mice hardly affects plasma TG levels whereas TG levels
are severely increased by APOC1 expression, indicating that apoCI has a profound additional effect.

Since the proposed functions of apoCI cannot explain the severe hypertriglyceridemic phenotype of APOC1 mice, the aim of the present study was to elucidate the main mechanism underlying the apoCI-induced combined hyperlipidemia in APOC1 mice. We demonstrate that apoCI is a potent inhibitor of LPL, which can explain the combined hyperlipidemia observed in APOC1 transgenic mice both in the presence and absence of endogenous apoE.

**Materials and Methods**

**Transgenic Animals**

Transgenic APOC1 mice with hemizygous expression of the human APOC1 gene have been generated previously as described,7,9 and back-crossed at least 10 times to C57Bl/6 background. APOC1 mice were intercrossed with apoE-deficient (apoe/-) mice (C57Bl/6 background) that have originally been obtained from the Jackson Laboratories (Bar Harbor, ME) to generate mice hemizygous for the APOC1 gene on an apoE-deficient background (apoe/-/APOC1). After initial characterization of both male and female mice, 10-12 weeks-old male APOC1 and apoe/-/APOC1 mice were used for subsequent experiments, with wild-type and apoe/- littermates as controls. Mice were housed under standard conditions in conventional cages and were fed ad libitum with regular chow (Ssniff, Soest, Germany). Experiments were performed after 4 h of fasting at 1:00 pm with food withdrawn at 9:00 am, unless stated otherwise.

**Plasma Lipid and Lipoprotein Analysis**

In all experiments blood was collected from the tail vein into chilled paraoxon (Sigma, St. Louis, MO)-coated capillary tubes to prevent ongoing in vitro lipolysis,27 unless indicated otherwise. These tubes were placed on ice, centrifuged at 4°C, and the obtained plasma was assayed for TC, TG (without free glycerol), and FFA using the commercially available enzymatic kits 236691 (Roche Molecular Biochemicals, Indianapolis, IN, USA), 337-B (GPO-Trinder kit; Sigma), and NEFA-C (Wako Chemicals, Neuss, Germany), respectively. For determination of the plasma lipoprotein distribution by fast performance liquid chromatography (FPLC), 50 µl of pooled plasma from 10 mice per group was injected onto a Superose 6 column (Äkta System; Amersham Pharmacia Biotech, Piscataway, NJ, USA), and eluted at a constant flow rate of 50 µl/min with PBS, 1 mM EDTA (Sigma), pH 7.4. Fractions of 50 µl were collected and assayed for TC and TG as described above. Human apoCI was quantified by ELISA as described below.

**VLDL-Isolation and Characterization**

Fasted mice were sacrificed by cervical dislocation and blood was drawn from the retroorbital vain into Microvette® CB 1000 Z capillaries (Sarstedt, Nümbrecht, Germany). Sera were collected after centrifugation at 4°C, and pooled from 10 mice. VLDL was isolated by flotation (d < 1.006 g/ml) after ultracentrifugation in a Beckman SW 40 Ti rotor (Beckman Instruments, Geneva, Switzerland) at 40,000 rpm during 18 h at 4°C.
The VLDL fractions were assayed for TG and TC as described above, and for free cholesterol (FC) and phospholipids (PL) using the commercially available analytical kits 274-47109 and 990-54009 (Wako Chemicals), respectively. Cholesteryl esters (CE) were calculated by subtracting the molar concentration of FC from the molar concentration of TC, and corrected for the presence of the fatty acid. Protein was determined by the method of Lowry et al. with BSA as a standard. VLDL-particle size was determined by photon correlation spectroscopy using a Zetasizer 3000 HSA (Malvern Instruments, Malvern, UK) at 25°C with a 90° angle between laser and detector.

**Human ApoCI ELISA**
Plasma human apoCI concentrations were determined using a human apoCI-specific sandwich ELISA. Hereeto, a polyclonal goat anti-human apoCI antibody (Academy Biomedical Company, Houston, TX, USA) was coated overnight onto Costar medium binding plates (Corning Incorporated, New York, NY) (dilution 1:10^4) at 4°C and incubated with diluted mouse plasma (dilution 1:10^6-10^7) or FPLC fractions (1:10^4), for 2 h at 4°C. Subsequently, horse radish peroxidase (HRP)-conjugated polyclonal goat anti-human apoCI antibody (dilution 1:500; Academy Biomedical Company) was added, incubated for 2 h at room temperature, and HRP was detected by incubation with tetramethylbenzidine (Organon Teknika, Boxtel, The Netherlands) for 20 min at room temperature. Plasma from wild-type mice spiked with human apoCI (Labconsult, Brussels, Belgium) was used as a standard.

**Intestinal Triglyceride Absorption**
*APOC1* mice and wild-type littersmates were fasted overnight and injected intravenously with 500 mg of Triton WR 1339 (Sigma) per kg body weight as a 10% (v/v) solution in sterile saline, to block LPL-mediated TG-hydrolysis. Subsequently, mice were given an intragastric load of glycerol tri[9,10(n)-3H]oleate (10 μCi; Amersham, Buckinghamshire, UK) ([3H]TO) in 200 µl of olive oil. Blood samples were drawn before and at the indicated times after olive oil administration by tail bleeding. Lipids were extracted from plasma according to the method of Bligh and Dyer, and TG was separated from the other lipid components by thin layer chromatography on Kieselgel 60 F254 plates (Merck, Darmstadt, Germany) by using hexane: diethyl ether: acetic acid (83: 16: 1, v/v/v) as eluens. The radioactivity in the TG fraction was determined by scintillation counting (Packard Instruments, Dowers Grove, IL) according to Voshol et al.

**Hepatic VLDL-Triglyceride Production**
Mice were fasted, anesthetized by intraperitoneal injection of domitor (0.5 mg/kg; Pfizer, New York, NY, USA), dormicum (5 mg/kg; Roche Netherlands, Mijdrecht, The Netherlands), and fentanyl (0.05 mg/kg; Janssen-Cilag B.V., Tilburg, The Netherlands), and injected via the tail vein with 500 mg of Triton WR1339 per kg body weight. Blood samples were drawn at 1, 30, 60, 90, and 120 min after administration and plasma TG levels were measured as described above.
Preparation and In Vivo Clearance of VLDL-Like Triglyceride-Rich Emulsion Particles

The preparation and characterization of 80 nm-sized protein-free VLDL-like emulsion particles have previously been described. Briefly, emulsion particles were prepared by sonication from 100 mg of total lipid at an egg yolk phosphatidylcholine (Lipoid, Ludwigshafen, Germany): triolein: lysophosphatidylcholine: cholesterol oleate: cholesterol (all from Sigma) weight ratio of 22.7: 2.3: 3.0: 2.0, in the presence of either 75 µCi of [3H]TO or 150 µCi of [1α,2α(n)-3H]cholesteryl oleate ([3H]CO; Amersham) using a Soniprep 150 (MSE Scientific Instruments, Crawley, UK) at 10 µm output. The lipid composition of the emulsions was determined as described above. Emulsions were stored at 4°C under argon and were used within 7 days. To study the in vivo serum clearance of the radiolabeled emulsions, mice were anesthetized as described above and the abdomens were opened. The emulsion (100 µg of TG), preincubated (30 min at 37°C) with or without human apoCI (50 µg), was injected intravenously via the vena cava inferior. When indicated, mice received a preinjection of bovine lactoferrin (70 mg/kg; Serva, Heidelberg, Germany) at 1 min before injection of the radiolabeled emulsion. Blood samples (< 50 µl) were taken via the vena cava inferior at the indicated times, and the radioactivity in serum was counted as described above. The total plasma volumes of the mice were calculated from the equation: V (ml) = 0.04706 x body weight (g), as determined from 125I-BSA clearance studies as previously described.

Plasma LPL Level Assay

Fasted APOC1 mice and wild-type littermates were injected via the tail vein with heparin (0.1 U/g; Leo Pharmaceutical Products B.V., Weesp, The Netherlands) and blood was collected after 10 min. The plasma thereof was snap-frozen and stored at -80°C until analysis of the total LPL activity as modified from Zechner. In short, a TG substrate mixture containing triolein (4.6 mg/ml), [3H]TO (2.5 µCi/ml), essentially fatty acid-free BSA (20 mg/ml; Sigma), Triton X-100 (0.1%; Sigma) and heat-inactivated (30 min 56°C) human serum (20%) in 0.1 M Tris-HCl, pH 8.6, was generated by 6 sonication periods of 1 min using a Soniprep 150 at 7 µm output, with 1 min intervals in between on ice. 10 µl of post-heparin plasma was added to 0.2 ml of substrate mixture and incubated for 30 min at 37°C in the presence or absence of 1 M NaCl, which completely inhibits LPL activity, to estimate both the LPL and HL levels. The reaction was stopped by the addition of 3.25 ml of heptane: methanol: chloroform (1: 1.28: 1.37, v/v/v), and 1 ml of 0.1 M K2CO3 in saturated H3BO3 (pH 10.5) was added. To quantify the generated [3H]oleate, 0.5 ml of the aqueous phase obtained after vigorous mixing (15 sec) and centrifugation (15 min at 3600 rpm) was counted in 4.5 ml of Ultima Gold (Packard Bioscience, Meriden, CT, USA). The LPL activity was calculated as the fraction of total triacylglycerol hydrolase activity inhibited by 1 M NaCl and expressed as the amount of FFA released per hour per ml of plasma.

In Vitro LPL Activity Assay
The effect of apolipoproteins on the TG hydrolysis of VLDL-like emulsion particles was determined as described. Hereto, [3H]TO-labeled emulsion particles (0.5 mg of TG/ml) were preincubated with apoCI, apoCIII (Labconsult), apoAI (Calbiochem, San Diego, CA, USA), or recombinant apoAV at the indicated TG: protein weight ratios (30 min at 37°C). Subsequently, the protein-enriched particles were incubated with LPL in the presence of essentially fatty acid-free BSA (60 mg/ml) and heat-inactivated human serum (5%) in 0.1 M Tris-HCl, pH 8.5. At the indicated times, 50 µl samples from a 400 µl total incubation volume were added to 1.5 ml methanol: chloroform: heptane: oleic acid (1410: 1250: 1000: 1, v/v/v/v) and 0.5 ml of 0.2 N NaOH to terminate lipolysis. Generated [3H]oleate was counted as described above and expressed as percentage of the total [3H]-activity added.

**Statistical Analysis**
Statistical differences with respect to in vivo serum half-lives were determined using a two-way main effects analysis of variance (ANOVA). All other data were analyzed using nonparametric Mann-Whitney U tests. P values less than 0.05 were regarded as significant.

**Results**

**Effect of APOC1 on Plasma ApoCI and Lipid Levels**
Table 1 summarizes the plasma human apoCI and lipid levels in fasted male APOC1 mice and wild-type littermates on chow diet. APOC1 mice had approximately 4-fold higher plasma levels of human apoCI as compared to humans, which was accompanied by severe combined hyperlipidemia. The enhancing effect of APOC1 expression on TG (12-fold) was much more pronounced than that on TC (2.1-fold) and FFA (1.5-fold), which is in agreement with our previous reports. Similar effects of human apoCI expression were observed in females as compared to males (data not shown). Lipoprotein fractionation by FPLC showed that the plasma human apoCI was primarily distributed towards HDL and VLDL (Fig. 1A). The increase in both plasma TG and TC as a result of APOC1 expression could be mainly attributed to highly elevated levels observed in VLDL and mildly increased levels in IDL/LDL, whereas the neutral lipid levels of the HDL-fraction were hardly affected (Figs. 1B and C).

**Effect of APOC1 in ApoE-Deficient Mice**
Although apoCI has been postulated to inhibit the apoE-dependent hepatic uptake of TG-rich lipoprotein remnants, apoE-deficient (apoE/-) mice show only minor elevation of plasma TG. To investigate the effects of APOC1 in the absence of endogenous apoE, APOC1 mice were intercrossed with apoE/- mice, to generate apoE/-APOC1 mice. Plasma human apoCI levels in apoE/-APOC1 mice were approximately 4-fold higher as compared to APOC1 mice, and severely further aggravated the hyperlipidemia as observed in apoE/- littermates (Table 1). Similar as on a wild-type background, APOC1 expression on an apoE/- background had a much more pronounced effect on TG (55-
Figure 1. Effect of APOC1 on FPLC profiles of human apoCI and lipids. Plasmas of male APOC1 (closed circle) and wild-type (open circle) mice (n=10) were pooled and size-fractionated by FPLC on a Superose 6 column. The individual fractions were analyzed for human apoCI (A), TG (B) and TC (C).

Table 1. Effect of APOC1 on plasma lipid levels in wild-type and apoe<sup>-/-</sup> mice.

| Genotype        | Human apoCI | TG       | TC       | FFA       |
|-----------------|-------------|----------|----------|-----------|
|                 | (mg/dl)     | (mmol/l) | (mmol/l) | (mmol/l)  |
| Wild-type background |             |          |          |           |
| Wild-type       | n.d.        | 0.32±0.06| 2.06±0.17| 0.79±0.15 |
| APOC1           | 39.7±9.4    | 3.86±0.75***| 4.28±0.57***| 1.18±0.20***|
| Apoe<sup>-/-</sup> background |             |          |          |           |
| Apoe<sup>-/-</sup> | n.d.        | 0.59±0.20| 11.0±5.2 | 0.78±0.13 |
| Apoe<sup>-/-</sup>APOC1 | 160±60   | 32.6±8.8***| 35.7±7.1** | 2.52±0.77***|

4 h fasted plasma was obtained from 10-12 weeks-old male APOC1 (n=23), wild-type (n=10), apoe<sup>-/-</sup>APOC1 (n=10) and apoe<sup>-/-</sup> (n=6) mice. Plasma human apoCI, TG, TC and FFA levels were measured and values are represented as means ± S.D. Statistical differences were assessed between APOC1 and wild-type mice, and between apoe<sup>-/-</sup>APOC1 and apoe<sup>-/-</sup> mice. **P<0.01, ***P<0.001; n.d., not detectable.
fold), than on TC (3.2-fold) and FFA (3.2-fold). Again, similar data were observed in females as compared to males (data not shown).

**Effect of APOC1 on VLDL Composition**

To investigate whether the effect of APOC1 expression on plasma lipid levels was accompanied by a change in VLDL composition and/or size, VLDL was isolated from apoe<sup>-/-</sup>APOC1 mice and their apoe<sup>-/-</sup> littermates, and their relative lipid compositions were determined (Table 2). The composition of VLDL from wild-type mice could not be determined accurately, because of low circulating levels (see Fig. 1). VLDL of apoe<sup>-/-</sup>APOC1 mice was predominantly enriched in TG, as compared to VLDL from apoe<sup>-/-</sup> littermates, and had a higher core lipid (TG + CE) to surface lipid (FC + PL) ratio (2.7 vs. 2.4, respectively), indicative for larger VLDL-particles. Indeed, VLDL particle size analysis confirmed that APOC1 expression markedly increased VLDL-size compared to control littermates, both on wild-type background (average size 72.9 vs. 44.4 nm, respectively) and apoe<sup> +/-</sup> background (average size 64.5 vs. 50.6 nm, respectively).

**Table 2. Effect of APOC1 on VLDL lipid composition.**

| Genotype       | TG      | CE      | FC      | PL      |
|----------------|---------|---------|---------|---------|
| Apoe<sup>-/-</sup> | 1.3     | 2.0     | 0.55    | 0.82    |
| Apoe<sup>-/-</sup>APOC1 | 3.0     | 0.94    | 0.56    | 0.89    |

VLDL (d<1.006 g/ml) was isolated from pooled plasma of fasted mice by ultracentrifugation and the TG, CE, FC, PL and protein content was measured.

**Effect of APOC1 on Intestinal Triglyceride Absorption and Hepatic VLDL-Triglyceride Production**

To further address the mechanism(s) underlying the hypertriglyceridemia in APOC1 mice, we determined whether the intestinal TG absorption and/or the hepatic VLDL-TG production rate were enhanced in these mice. First, the intestinal TG absorption was studied by injecting intravenously Triton WR1339, to block LPL-mediated TG-hydrolysis, after which an intragastric load of olive oil containing [3H]TO was given. As shown in Fig. 2, no differences were observed between APOC1 and wild-type mice with respect to appearance of radioactivity in plasma TG, indicating that apoCI expression does not enhance triglyceride absorption from the intestinal lumen.

The hepatic VLDL-TG production rate was measured by determining plasma TG levels at the indicated times after intravenous Triton WR1339 injection (Fig. 3). Whereas the TG levels in the APOC1 mice were higher as compared to the wild-type littermates at the start of the experiment (4.9 ± 2.1 vs. 0.42 ± 0.08 mM, respectively; Fig. 3A), the relative increase in TG was similar for both types of mice (7.4 ± 0.9 vs. 6.6 ± 0.8 mM/h,
respectively). Likewise, we found no difference in the relative increase in TG levels in apoe<sup>-/-</sup>APOC<sub>1</sub> as compared to apoe<sup>-/-</sup> mice (3.3 ± 1.4 vs 3.1 ± 0.7 mM/h, respectively; Fig. 3B), indicating that apoCI expression does not affect the hepatic VLDL-TG production rate either.
ApoCI Inhibits LPL In Vivo

**Effect of APOC1 on In Vivo Clearance of VLDL-Like Emulsion Particles**
To investigate whether an impaired lipolytic processing of TG-rich lipoproteins may contribute to the hypertriglyceridemia observed in APOC1 mice, mice were injected with [3H]TO-labeled protein-free VLDL-like emulsion particles, which have previously been shown to mimic the metabolic behaviour of TG-rich lipoproteins.\(^{33,38}\) As shown in Fig. 4, the clearance of [3H]TO was markedly decreased in APOC1 mice compared to their wild-type littermates, as evident from a 2-fold increased serum half-life of [3H]TO (7.9 ± 2.1 vs. 4.0 ± 0.3 min, respectively; \(P < 0.05\)). This observation indicates that APOC1 expression impairs TG clearance, which may result from inhibition of the LPL-mediated VLDL-TG hydrolysis.

![Figure 4. Effect of APOC1 on serum clearance of VLDL-like emulsion particles in vivo.](image)

Effect of APOC1 on Plasma LPL Levels
An impaired clearance of VLDL-TG in APOC1 mice can be due to either a decreased expression of LPL and/or apoCI-induced inhibition of the activity of LPL. Therefore, we first determined plasma lipase levels in post-heparin plasma by incubation with a [3H]TO-containing substrate mixture (Fig. 5). Whereas the post-heparin HL level was only slightly increased in APOC1 mice as compared to wild-type littermates (12.8 ± 1.2 vs. 11.3 ± 1.0 µmol FFA/h/ml, respectively; \(P < 0.05\)), the post-heparin LPL level was even 1.8-fold increased in APOC1 mice as compared to wild-type mice (40.7 ± 6.1 vs. 22.5 ± 2.2 µmol FFA/h/ml, respectively; \(P < 0.01\)). Therefore, the impaired lipolytic conversion of VLDL in APOC1 mice cannot be due to decreased levels of LPL.

**Effect of ApoCI on LPL Activity**
To investigate whether the apoCI-related impaired lipolytic conversion of VLDL can be due to a direct inhibiting effect of apoCI on LPL activity, protein-free VLDL-like emul-
sion particles were enriched with increasing concentrations of purified human apoCI and subsequently incubated with LPL. The well-established endogenous LPL inhibitor apoCIII\textsuperscript{39,40} was used as a control. ApoCI and apoCIII were compared on a mass basis,

Figure 5. Effect of APOC1 on plasma HL and LPL levels in vivo. Fasted APOC1 (closed bars) and wild-type (open bars) mice were injected intravenously with heparin (0.1 U/g). Plasma, collected at 10 min after injection, was incubated (30 min at 37°C) with a [\textsuperscript{3}H]TO containing substrate mixture in the absence or presence of 1 M NaCl, to estimate both the LPL and HL activity. Generated [\textsuperscript{3}H]oleate was extracted and determined as described. Values represent means ± S.D. (n=8). *P<0.05, **P<0.01.

Figure 6. Effect of apoCI on LPL-mediated hydrolysis of VLDL-like emulsion triglycerides. (A) [\textsuperscript{3}H]TO-labeled protein-free emulsion particles were preincubated (30 min at 37°C) in the absence (open circle) and presence of apoCI at TG:apoCI = 50:3 (open triangle), 50:5 (closed triangle), and 50:10 (open square) weight ratios. At the indicated times after addition of LPL, generated [\textsuperscript{3}H]oleate was extracted and quantified. (B) The effect of apoCI (closed circle) on LPL-mediated TG hydrolysis was compared with that of apoCIII (open circle), and depicted as percentage of the TG hydrolysis rate in the absence of protein.
ApoCI Inhibits LPL In Vivo

as they are also present in human plasma at similar mass concentrations (i.e. 10 and 13 mg/dl). ApoCI appeared to dose-dependently inhibit the TG hydrolysis rate (Fig. 6A). At a TG: protein = 50:10 weight ratio, apoCI and apoCIII inhibited the triacylglycerol hydrolase activity of LPL by 33% and 55%, respectively (Fig. 6B). In contrast, apoAI did not affect lipolysis, and apoAV even dose-dependently increased the lipolysis rate up to 1.5-fold at a TG: apoAV = 50:3 weight ratio (data not shown), which is in agreement with our previous observations.

Effect of ApoCI-Enrichment of VLDL-Like Emulsion Particles on In Vivo Clearance

To assess whether apoCI can directly inhibit lipolysis in vivo, the effect of apoCI protein was determined on the plasma decay of [3H]TO-labeled protein-free VLDL-like emulsion particles in wild-type mice. To focus on the effects of apoCI on peripheral lipolysis rather than on liver uptake, mice were preinjected with lactoferrin. Lactoferrin has previously been shown to block the interaction of chylomicrons and emulsion particles with the liver in vivo, which we confirmed using [3H]CO-labeled protein-free VLDL-like emulsion particles (results not shown). As depicted in Figure 7, preincubation of emulsion particles with apoCI markedly delayed the clearance of [3H]TO as evident from a 1.9-fold increased serum half-life (17.6 ± 5.7 vs. 9.2 ± 3.7 min, respectively; P<0.05), indicating that apoCI can indeed inhibit the lipolytic TG conversion in vivo.

Figure 7. Effect of human apoCI-enrichment of VLDL-like emulsion particles on their serum clearance in lactoferrin-treated mice. [3H]TO-labeled emulsion particles (100 µg of TG) were preincubated without (open circle) or with (closed circle) human apoCI (50 µg) for 30 min at 37°C, and injected via the vena cava inferior into anesthetized lactoferrin-treated wild-type mice. Blood samples were taken at the indicated times, and 3H-activity was determined in serum. Values are means ± S.E.M. (n=3). *P<0.05.
Chapter 2

Discussion

Studies in both humans and mice have shown that increased expression of apoCI results in combined hyperlipidemia, with a more pronounced enhancing effect on TG as compared to TC. Since a variety of effects on lipid metabolism has been attributed to apoCI, including activatory effects (e.g. LCAT) and inhibitory effects (e.g. HL, CETP, intestinal absorption, and apoE-dependent recognition by LRP, LDLr and VLDLr), the aim of the present study was to elucidate the main mechanism underlying the apoCI-related hypertriglyceridemia using APOCI transgenic mice. We demonstrated that at moderate plasma human apoCI levels (i.e. 4-fold higher than those found in humans), the 12-fold increase in plasma TG levels was mainly due to inhibition of the lipolytic processing of VLDL.

The effects of apoCI on lipid metabolism were mainly confined to VLDL metabolism, leaving HDL metabolism (which crucially involves both CETP and LCAT) unaffected. Analysis of the HDL-protein constituents for CETP-modulating properties showed that apoCI is a very potent and highly selective inhibitor of CETP. In addition, Gautier et al. have shown that cross-breeding of human CETP transgenic mice with apoCI-deficient mice resulted in a higher CETP activity in vivo. Although apoCI thus appears to be a physiologically relevant inhibitor of CETP, this function of apoCI cannot contribute to the phenotype of APOCI mice, since mice do not express CETP. Activation of LCAT should be expected to lead to increased HDL size and HDL lipids as was observed in mice and rabbits that overexpress LCAT. Since both the cholesterol level and size of HDL are not affected by apoCI expression in APOCI mice, potential LCAT-activating properties of apoCI do not appear to be relevant for determining HDL levels in mice.

ApoCI expression thus predominantly affects VLDL-TG metabolism, which can result from either i) increased intestinal TG absorption, ii) increased VLDL-TG production, and/or iii) disturbed lipolytic conversion and/or hepatic clearance of VLDL. Previously, we have reported that mice deficient for apoCI showed a significantly lower intestinal lipid absorption as compared to wild-type mice. However, no changes in intestinal lipid absorption were observed in APOCI mice as compared to wild-type littersmates, which can be related to a relatively low expression of human apoCI in the intestine. Previously, we have shown that apoE-deficient mice show a decreased VLDL-TG secretion rate, and we confirm this observation in our present study. Although human apoCI is highly expressed in the liver, we did not detect any effect of human apoCI expression on hepatic VLDL-TG production rate on both a wild-type and apoE-deficient background, which is in line with our previous studies showing that apoCI-deficiency did not alter the hepatic VLDL production rate. Apparently, expression of human apoCI can not compensate for the decreased VLDL-TG production in apoE-deficient mice. Collectively, the hypertriglyceridemia in APOCI mice is not caused by either an effect on intestinal TG absorption or hepatic TG production.

Next, we evaluated the effect of apoCI expression on apoE-dependent VLDL uptake by the liver. ApoCI has been shown to inhibit the apoE-mediated binding of TG-rich lipoprotein remnants by hepatic lipoprotein receptors (i.e. LDLr and LRP), although Quarfordt et al. reported that the apoCI-mediated inhibition of the uptake of TG-rich
emulsions by cultured hepatocytes was (at least partly) independent on the presence of apoE. Indeed, we have shown that APOC1 expression in mice can interfere with hepatic interaction of VLDL primarily via LRP. However, the contribution of this effect to the APOC1-induced severe hypertriglyceridemia can be questioned since complete blockade of the apoE-dependent hepatic lipoprotein clearance in apoe/− mice only mildly affects plasma TG levels, whereas APOC1 expression increases plasma TG as much as 12-fold. In addition, we now show that APOC1 expression on an apoe/− background further dramatically increased TG levels, showing that the hypertriglyceridemic effects of apoC1 can be independent of the presence of apoE. Taken together, these data indicate that the hypertriglyceridemia observed in APOC1 mice can also not be explained by inhibition of apoE-mediated hepatic remnant uptake.

Finally, we evaluated the possibility that the lipolytic conversion of VLDL may be impaired in APOC1 mice, since such a mechanism may explain the dramatic accumulation of plasma TG in primarily VLDL. In addition, a decreased plasma TG hydrolysis may also explain the increased VLDL particle size observed in APOC1 expressing mice on both wild-type and apoe/− background, and the observed impaired clearance of VLDL-like emulsion particles upon intravenous administration.

Recently, Conde-Knape et al. described the cross-breeding of their human apoCI-expressing mouse strain with apoe/− mice, which resulted in a comparable, albeit more modest, hypertriglyceridemic phenotype as our apoe/−:APOC1 mice, and they suggested that the hypertriglyceridemia in these mice was due to inhibition of HL-mediated TG-hydrolysis. However, HL-deficiency or overexpression in mice and rabbits predominantly affects plasma HDL-TC levels with only mild effects (if any) on TG levels on both wild-type and apoe/− backgrounds. Furthermore, HL has a much lower preference for TG as compared to LPL and HL is known to primarily mediate the conversion of IDL to LDL, and of HDL₂ to HDL₃, while both our studies and those of Conde-Knape et al. indicate that APOC1 expressing mice merely have a disturbed VLDL metabolism. Therefore, although a potential inhibiting effect of apoC1 on the activity of HL in vivo cannot be ruled out, and it may add to the observed hypercholesterolemia, it does not contribute to the severe hypertriglyceridemia observed in APOC1 mice.

Thus, impairment of LPL remains as the most likely mechanism explaining the hypertriglyceridemic phenotype of APOC1 mice. Although the APOC1 mice showed elevated LPL levels in postheparin plasma, we indeed found that apoC1 is very effective in attenuating the LPL activity in vitro, with a 60% efficiency on mass basis as compared to the well-known endogenous LPL-inhibitor apoCIII. Our observations confirm previous in vitro studies by Havel et al. who showed that apoC1 and apoCIII were equally effective on a mass basis with respect to inhibition of the apoCII-stimulated LPL-mediated TG hydrolysis. In fact, the LPL-inhibitory properties of apoC1 and apoCIII are specific for these apolipoproteins, since addition of the negative control apoAI had no effect on the LPL activity, and the recently identified LPL-stimulator apoAV enhanced the LPL activity in this assay. Importantly, the TG:apoC1 ratios applied in the in vitro assay at which apoC1 inhibited LPL (50: 3-10, w/w) were similar as found in both APOC1 mice (50: 6) and apoe/−:APOC1 mice (50: 3), indicating that the LPL-inhibitory properties observed in vitro are relevant for the in vivo situa-
Chapter 2

Indeed, preincubation of VLDL-like emulsion particles with apoCI inhibited the liver-independent serum clearance of emulsion-TG, as was demonstrated in lactoferrin-treated mice. Concomitantly, the uptake of TG-derived fatty acids by white adipose tissue was 1.8-fold decreased (not shown). Given the fact that apoCI readily exchanges between lipoproteins, a part of the injected emulsion-associated apoCI will presumably rapidly redistribute towards endogenous lipoproteins, which will even lead to underestimation of the inhibiting effect of apoCI on emulsion-TG clearance. In a previous study from our group in which VLDL clearance was assessed in functionally hepatectomized APOC1 mice on a LFC diet, we also found a tendency towards a decreased VLDL-TG lipolysis rate in APOC1 mice (i.e. 32%), albeit that a statistically significant difference was not reached under the applied experimental conditions.9

The phenotype of APOC1 mice closely resembles that of human apoCIII-expressing APOC3 mice with respect to predominant elevation of VLDL-TG levels.54 In addition, both APOC1 mice and APOC3 mice show a modest increase in plasma cholesterol levels. In fact, the relative increase in TG as compared to cholesterol as induced by apo-Cl-expression (i.e. 5.8) is similar to that as induced by apoCIII expression (i.e. 5.5).54 Indeed, it has been established that LPL activity strongly determines plasma TG levels. Overexpression of LPL in mice markedly reduces plasma VLDL-TG levels,53,54 whereas heterozygous deficiency of LPL results in accumulation of plasma VLDL-TG.55 Similar to APOC1 and APOC3 mice, the effects of LPL modulation on plasma TG exceeded those on TC.

Inhibition of the lipolytic conversion of TG-rich lipoproteins in APOC1 mice can fully account for our previous observation that APOC1 protects against the development of obesity on a genetically obese leptin-deficient (ob/ob) background,56 by impeding the disposition of LPL-liberated fatty acids into adipose tissue. Likewise, we have recently observed that deletion of the main endogenous LPL-inhibitor apoCIII in apoc3/- mice markedly aggravates diet-induced obesity as related to increased adipose tissue stores (unpublished observations). Interestingly, we have reported that VLDLr-deficient (vldlr/-) mice are protected from diet-induced obesity on both a wild-type and ob/ob background.57 Subsequently, Yagyu et al.58 have shown that vldlr/- mice have reduced LPL activity as related to the LPL-chaperone function of the VLDLr,59 which may partially explain their resistance to obesity. In addition, the VLDLr may also be involved in LPL-mediated lipolysis by bridging of lipoproteins to the endothelial surface, thereby facilitating the LPL-particle interaction. Since we have firmly established that apoCI strongly inhibits the interaction of VLDL with the VLDLr,24 a concurring VLDLr-inhibiting effect of apoCI may certainly add to further hampering of the LPL-mediated VLDL-TG hydrolysis in vivo as observed in APOC1 mice.

In conclusion, we have demonstrated that the hypertriglyceridemic effect of moderate human apoCI expression in mice is the consequence of an impaired lipolytic conversion of VLDL-TG. This effect probably results from a direct inhibiting effect of apoCI on LPL activity, although a concomitant inhibiting effect of apoCI on VLDL binding to the VLDLr, which facilitates lipolysis, cannot be excluded. The mechanism by which apoCI inhibits LPL activity is currently under investigation.
References

1. Scott J, Knott TJ, Shaw DJ, Brook JD. Localization of genes encoding apolipoproteins Cl, CII, and E to the p13-cen region of human chromosome 19. Hum Genet. 1985;71:144-146.

2. Lauer SJ, Walker D, Elshourbagy NA, Reedon CA, Levy-Wilson B, Taylor JM. Two copies of the human apolipoprotein C-I gene are linked closely to the apolipoprotein E gene. J Biol Chem. 1988;263:7277-7286.

3. Cohn JS, Tremblay M, Boulet L, Jacques H, Davignon J, Roy M, Bernier L. Plasma concentration and lipoprotein distribution of ApoC-I is dependent on ApoE genotype rather than the Hpa I ApoC-I promoter polymorphism. Atherosclerosis. 2003;169:63-70.

4. Shulman RS, Herbert PN, Wehrly K, Fredrickson DS. Thy complete amino acid sequence of C-I (apoLp-Ser), an apolipoprotein from human very low density lipoproteins. J Biol Chem. 1975;250:182-190.

5. Xu Y, Berglund L, Ramakrishnan R, Mayeux R, Ngai C, Holleran S, Tycko B, Leff T, Shachter NS. A common Hpa I RFLP of apolipoprotein C-I increases gene transcription and exhibits an ethnically distinct pattern of linkage disequilibrium with the alleles of apolipoprotein E. J Lipid Res. 1999;40:50-58.

6. Hubacek JA, Pitha J, Adamkova V, Skodova Z, Larska V, Poledne R. Apolipoprotein E and apolipoprotein Cl polymorphisms in the Czech population: almost complete linkage disequilibrium of the less frequent alleles of both polymorphisms. Physiol Res. 2003;52:195-200.

7. Jong MC, van Ree JH, Dahlmans VE, Frants RR, Hofker MH, Havekes LM. Reduced very-low-density lipoprotein fractional catabolic rate in apolipoprotein C1-deficient mice. Biochem J. 1997;321 (Pt 2):445-450.

8. van Ree JH, Hofker MH, van den Broek WJ, van Deursen JM, van der BH, Frants RR, Wieringa B, Havekes LM. Increased response to cholesterol feeding in apolipoprotein C1-deficient mice. Biochem J. 1995;305 (Pt 3):905-911.

9. Jong MC, Dahlmans VE, van Gorp PJ, van Dijk KW, Breuer ML, Hofker MH, Havekes LM. In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway. J Clin Invest. 1996;98:2259-2267.

10. Shachter NS, Ebara T, Ramakrishnan R, Steiner G, Breslow JL, Ginsberg HN, Smith JD. Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein C1. J Clin Invest. 1996;98:846-855.

11. Jong MC, Gijbels MJ, Dahlmans VE, Gorp PJ, Koopman SJ, Ponec M, Hofker MH, Havekes LM. Hyperlipidemia and cutaneous abnormalities in transgenic mice overexpressing human apolipoprotein C1. J Clin Invest. 1998;101:145-152.

12. Soutar AK, Garner CW, Baker HN, Sparrow JT, Jackson RL, Gotto AM, Smith LC. Effect of the human plasma apolipoproteins and phosphatidylcholine acyl donor on the activity of lecithin: cholesterol acyltransferase. Biochemistry. 1975;14:3057-3064.

13. Havel RJ, Fielding CJ, Olivecrona T, Shore VG, Fielding PE, Egelrud T. Cofactor activity of protein components of human very low density lipoproteins in the hydrolysis of triglycerides by lipoproteins lipase from different sources. Biochemistry. 1973;12:1828-1833.

14. Kinnunen PK and Ehnoml C. Effect of serum and C-apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipase. FEBS Lett. 1976;65:354-357.

15. Conde-Knape K, Bensadoun A, Sobel JH, Cohn JS, Shachter NS. Overexpression of apoC-I in apoE-null mice: severe hypertriglyceridemia due to inhibition of hepatic lipase. J Lipid Res. 2002;43:2136-2145.

16. Applebaum-Bowden D, Kobayashi J, Kashyap VS, Brown DR, Berard A, Meyn S, Parrott C, Maeda N, Shamberek R, Brewer HB, Jr., Santamarina-Fojo S. Hepatic lipase gene therapy in hepatic lipase-deficient mice. Adenovirus-mediated replacement of a lipolytic enzyme to the vascular endothelium. J Clin Invest. 1996;97:799-805.
17. Homanics GE, de Silva HV, Osada J, Zhang SH, Wong H, Borensztajn J, Maeda N. Mild dyslipidemia in mice following targeted inactivation of the hepatic lipase gene. J Biol Chem. 1995;270:2974-2980.

18. Mezdour H, Jones R, Dengremont C, Castro G, Maeda N. Hepatic lipase deficiency increases plasma cholesterol but reduces susceptibility to atherosclerosis in apolipoprotein E-deficient mice. J Biol Chem. 1997;272:13570-13575.

19. Francone OL, Gong EL, Ng DS, Fielding CJ, Rubin EM. Expression of human lecithin-cholesterol acyltransferase in transgenic mice. Effect of human apolipoprotein AI and human apolipoprotein all on plasma lipoprotein cholesterol metabolism. J Clin Invest. 1995;96:1440-1448.

20. Quarfordt SH, Michalopoulos G, Schirmer B. The effect of human C apolipoproteins on the in vitro hepatic metabolism of triglyceride emulsions in the rat. J Biol Chem. 1982;257:14642-14647.

21. Windler E and Havel RJ. Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver. J Lipid Res. 1983;26:536-565.

22. Sehayek E and Eisenberg S. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J Biol Chem. 1991;266:281-287.

23. Weisgraber KH, Mahley RW, Kowal RC, Herz J, Goldstein JL, Brown MS. A polipoprotein C-I modulates the interaction of apolipoprotein E with beta-migrating very low density lipoproteins (beta-VLDL) and inhibits binding of beta-VLDL to low density lipoprotein receptor-related protein. J Biol Chem. 1990;265:22453-22459.

24. Jong MC, van Dijk KW, Dahlmans VE, van der BH, Kobayashi K, Oka K, Siest G, Chan L, Hofker MH, Havekes LM. Reversal of hyperlipidemia in apolipoprotein C1 transgenic mice by adenosine-mediated gene delivery of the low-density-lipoprotein receptor, but not by the very-low-density-lipoprotein receptor. Biochem J. 1999;338 (Pt 2):281-287.

25. Mensenkamp AR, Jong MC, van Goor H, van Luyn MJ, Bloks V, Havinga R, Voshol PJ, Hofker MH, van Dijk KW, Havekes LM, Kuipers F. A polipoprotein E participates in the regulation of very low density lipoprotein-triglyceride secretion by the liver. J Biol Chem. 1999;274:35711-35718.

26. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992;71:343-353.

27. Zambon A, Hashimoto SI, Brunzell JD. Analysis of techniques to obtain plasma for measurement of levels of free fatty acids. J Lipid Res. 1993;34:1021-1028.

28. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.

29. Borensztajn J, Rone MS, Kotlar TJ. The inhibition in vivo of lipoprotein lipase (clearing-factor lipase) activity by triton WR-1339. Biochem J. 1976;156:539-543.

30. Bligh EG and Dyer WJ. A rapid method of total lipid extraction and purification. Can J Med Sci. 1959;37:911-917.

31. Voshol PJ, Minich DM, Havinga R, Elferink RP, Verkade HJ, Groen AK, Kuipers F. Postprandial chylomicron formation and fat absorption in multidrug resistance gene 2 P-glycoprotein-deficient mice. Gastroenterology. 2000;118:173-182.

32. Jong MC, Dahlmans VE, van Gorp PJ, Breuer ML, Mol MJ, van der ZA, Frants RR, Hofker MH, Havekes LM. Both lipolysis and hepatic uptake of VLDL are impaired in transgenic mice coexpressing human apolipoprotein E*3Leiden and human apolipoprotein C1. Arterioscler Thromb Vasc Biol. 1996;16:934-940.

33. Rensen PC, Herijgers N, Netscher MH, Meskers SC, van Eck M, van Berkel TJ. Particle size determines the specificity of apolipoprotein E-containing triglyceride-rich emulsions for the LDL receptor versus hepatic remnant.
receptor in vivo. J Lipid Res. 1997;38:1070-1084.
34. Jong MC, Rensen PC, Dahlmans VE, van der BH, van Berkel TJ, Havekes LM. Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice. J Lipid Res. 2001;42:1578-1585.
35. Zechnner R. Rapid and simple isolation procedure for lipoprotein lipase from human milk. Biochim Biophys Acta. 1990;1044:20-25.
36. Rensen PC and van Berkel TJ. Apolipoprotein E effectively inhibits lipoprotein lipase-mediated lipolysis of chylomicron-like triglyceride-rich lipid emulsions in vitro and in vivo. J Biol Chem. 1996;271:14791-14799.
37. Schaap FG, Rensen PC, Voshol PJ, Vrins C, van der Vliet HN, Chamuleau RA, Havekes LM, Groen AK, van Dijk KW. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J Biol Chem. 2004;279:27941-27947.
38. Rensen PC, Jong MC, van Vark LC, van der BH, Hendriks WL, van Berkel TJ, Biessen EA, Havekes LM. Apolipoprotein E is resistant to intracellular degradation in vitro and in vivo. Evidence for retroendocytosis. J Biol Chem. 2000;275:8564-8571.
39. McConathy WJ, Gesquiere JC, Bass H, Tartar A, Fruchart JC, Wang CS. Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. J Lipid Res. 1992;33:995-1003.
40. Wang CS, McConathy WJ, Kloer HU, Alauopovic P. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest. 1985;75:384-390.
41. van Dijk MC, Ziere GJ, Boers W, Linthorst C, Bijsterbosch MK, van Berkel TJ. Recognition of chylomicron remnants and beta-migrating very-low-density lipoproteins by the remnant receptor of parenchymal liver cells is distinct from the liver alpha 2-macroglobulin-recognition site. Biochem J. 1991;279 (Pt 3):863-870.
42. Gautier T, Masson D, de Barros JP, Athias A, Gambert P, Aunis D, Metz-Boutigue MH, Lagrost L. Human apolipoprotein C-I accounts for the ability of plasma high density lipoproteins to inhibit the cholesteryl ester transfer protein activity. J Biol Chem. 2000;275:37504-37509.
43. Gautier T, Masson D, Jong MC, Duverneuil L, Le Guern N, Deckert V, Pais De Barros JP, Dumont L, Bataille A, Zak Z, Jiang XC, Tall AR, Havekes LM, Lagrost L. Apolipoprotein CI deficiency markedly augments plasma lipoprotein changes mediated by human cholesteryl ester transfer protein (CETP) in CETP transgenic/ApoCI-knocked out mice. J Biol Chem. 2002;277:31354-31363.
44. Jiao S, Cole TG, Kitchens RT, Pfleger B, Schonfeld G. Genetic heterogeneity of lipoproteins in inbred strains of mice: analysis by gel-permeation chromatography. Metabolism. 1990;39:155-160.
45. Hoeg JM, Vaisman BL, Demosky SJ, Jr., Meyn SM, Talley GD, Hoyt RF, Jr., Feldman S, Berard AM, Sakai N, Wood D, Broussseau ME, Marcovina S, Brewer HB, Jr., Santamarina-Fojo S. Lecithin:cholesterol acyltransferase overexpression generates hyperal-pa-lipoproteinemia and a nonatherogenic lipoprotein pattern in transgenic rabbits. J Biol Chem. 1996;271:4396-4402.
46. Kowal RC, Herz J, Weisgraber KH, Mahley RW, Brown MS, Goldstein JL. Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J Biol Chem. 1990;265:10771-10779.
47. Fan J, Wang J, Bensadoun A, Lauer SJ, Dang Q, Mahley RW, Taylor JM. Overexpression of hepatic lipase in transgenic rabbits leads to a marked reduction of plasma high density lipoproteins and intermediate density lipoproteins. Proc Natl Acad Sci U S A. 1994;91:8724-8728.
48. McCoy MG, Sun GS, Marchadier D, Maugeais C, Glick JM, Rader DJ. Characterization of the lipolytic activity of endothelial lipase. J Lipid Res. 2002;43:921-929.
49. Applebaum-Bowden D. Lipases and lecithin: cholesterol acyltransferase in the control of lipoprotein metabolism. Curr Opin Lipidol. 1995;6:130-135.
50. Brown WV and Baginsky ML. Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochem Biophys Res Commun. 1972;46:375-382.

51. Ito Y, Azrolan N, O’Connell A, Walsh A, Breslow JL. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science. 1990;249:790-793.

52. Aalto-Setala K, Weinstock PH, Bisgaier CL, Wu L, Smith JD, Breslow JL. Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice. J Lipid Res. 1996;37:1802-1811.

53. Excoffon KJ, Liu G, Miao L, Wilson JE, McManus BM, Semenkovich CF, Coleman T, Benoit P, Duverger N, Branellec D, Denefle P, Hayden MR, Lewis ME. Correction of hypertriglyceridemia and impaired fat tolerance in lipoprotein lipase-deficient mice by adenovirus-mediated expression of human lipoprotein lipase. Arterioscler Thromb Vasc Biol. 1997;17:2532-2539.

54. Shimada M, Shimano H, Gotoda T, Yamamoto K, Kawamura M, Inaba T, Yazaki Y, Yamada N. Overexpression of human lipoprotein lipase in transgenic mice. Resistance to diet-induced hypertriglyceridemia and hypercholesterolemia. J Biol Chem. 1993;268:17924-17929.

55. Coleman T, Seip RL, Gimble JM, Lee D, Maeda N, Semenkovich CF. COOH-terminal disruption of lipoprotein lipase in mice is lethal in homozygotes, but heterozygotes have elevated triglycerides and impaired enzyme activity. J Biol Chem. 1995;270:12518-12525.

56. Jong MC, Voshol PJ, Muurling M, Dahlmans VE, Romijn JA, Pijl H, Havekes LM. Protection from obesity and insulin resistance in mice overexpressing human apolipoprotein C1. Diabetes. 2001;50:2779-2785.

57. Goudriaan JR, Tacken PJ, Dahlmans VE, Gijbels MJ, van Dijk KW, Havekes LM, Jong MC. Protection from obesity in mice lacking the VLDL receptor. Arterioscler Thromb Vasc Biol. 2001;21:1488-1493.

58. Yagyu H, Lutz EP, Kako Y, Marks S, Hu Y, Choi SY, Bensadoun A, Goldberg IJ. Very low density lipoprotein (VLDL) receptor-deficient mice have reduced lipoprotein lipase activity. Possible causes of hypertriglyceridemia and reduced body mass with VLDL receptor deficiency. J Biol Chem. 2002;277:10037-10043.

59. Obunike JC, Lutz EP, Li Z, Paka L, Katopodis T, Strickland DK, Kozarsky KF, Pillarisetti S, Goldberg IJ. Transcytosis of lipoprotein lipase across cultured endothelial cells requires both heparan sulfate proteoglycans and the very low density lipoprotein receptor. J Biol Chem. 2001;276:8934-8941.